Limits...
A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.

Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Brighina F, Fierro B - J Headache Pain (2011)

Bottom Line: No significant differences were observed in sustained pain free episodes (21% vs. 18%).The tolerability profile was similar between the two drugs.In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.

View Article: PubMed Central - PubMed

Affiliation: G. D’Annunzio University, Chieti, Italy.

ABSTRACT
The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain free and pain relief episodes at 2 and 4 h, and recurrent and sustained pain free episodes within 48 h. Of the 133 patients (86%, intention-to-treat population) 114 of them expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (3.1 ± 1.3) and almotriptan (3.4 ± 1.3). The rates of pain free (30% frovatriptan vs. 32% almotriptan) and pain relief (54% vs. 56%) episodes at 2 h did not significantly differ between treatments. This was the case also at 4 h (pain free: 56% vs. 59%; pain relief: 75% vs. 72%). Recurrent episodes were significantly (P < 0.05) less frequent under frovatriptan (30% vs. 44%), also for the attacks treated within 30 min. No significant differences were observed in sustained pain free episodes (21% vs. 18%). The tolerability profile was similar between the two drugs. In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.

Show MeSH

Related in: MedlinePlus

Cumulative hazard of recurrence over the 48 h during treatment with frovatriptan or almotriptan, in the 114 patients of the whole study population and for attacks for which the drug was taken within 30 min from the onset of the episode
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3094646&req=5

Fig2: Cumulative hazard of recurrence over the 48 h during treatment with frovatriptan or almotriptan, in the 114 patients of the whole study population and for attacks for which the drug was taken within 30 min from the onset of the episode

Mentions: Conversely, the rate of recurrent episodes at 48 h was significantly (P < 0.05) lower under frovatriptan, both when defined according to the protocol (28% vs. 34% almotriptan) or to IHS criteria (30% vs. 44%). This was the case also when recurrence was expressed as a cumulative hazard ratio over the observation period (Fig. 2, left panel).Fig. 2


A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine.

Bartolini M, Giamberardino MA, Lisotto C, Martelletti P, Moscato D, Panascia B, Savi L, Pini LA, Sances G, Santoro P, Zanchin G, Omboni S, Ferrari MD, Brighina F, Fierro B - J Headache Pain (2011)

Cumulative hazard of recurrence over the 48 h during treatment with frovatriptan or almotriptan, in the 114 patients of the whole study population and for attacks for which the drug was taken within 30 min from the onset of the episode
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3094646&req=5

Fig2: Cumulative hazard of recurrence over the 48 h during treatment with frovatriptan or almotriptan, in the 114 patients of the whole study population and for attacks for which the drug was taken within 30 min from the onset of the episode
Mentions: Conversely, the rate of recurrent episodes at 48 h was significantly (P < 0.05) lower under frovatriptan, both when defined according to the protocol (28% vs. 34% almotriptan) or to IHS criteria (30% vs. 44%). This was the case also when recurrence was expressed as a cumulative hazard ratio over the observation period (Fig. 2, left panel).Fig. 2

Bottom Line: No significant differences were observed in sustained pain free episodes (21% vs. 18%).The tolerability profile was similar between the two drugs.In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.

View Article: PubMed Central - PubMed

Affiliation: G. D’Annunzio University, Chieti, Italy.

ABSTRACT
The objective of this study was to evaluate patients' satisfaction with acute treatment of migraine with frovatriptan or almotriptan by preference questionnaire. One hundred and thirty three subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or almotriptan 12.5 mg, treating 1-3 attacks. The study had a multicenter, randomized, double blind, cross-over design, with treatment periods lasting <3 months. At study end patients assigned preference to one of the treatments using a questionnaire with a score from 0 to 5 (primary endpoint). Secondary endpoints were pain free and pain relief episodes at 2 and 4 h, and recurrent and sustained pain free episodes within 48 h. Of the 133 patients (86%, intention-to-treat population) 114 of them expressed a preference for a triptan. The average preference score was not significantly different between frovatriptan (3.1 ± 1.3) and almotriptan (3.4 ± 1.3). The rates of pain free (30% frovatriptan vs. 32% almotriptan) and pain relief (54% vs. 56%) episodes at 2 h did not significantly differ between treatments. This was the case also at 4 h (pain free: 56% vs. 59%; pain relief: 75% vs. 72%). Recurrent episodes were significantly (P < 0.05) less frequent under frovatriptan (30% vs. 44%), also for the attacks treated within 30 min. No significant differences were observed in sustained pain free episodes (21% vs. 18%). The tolerability profile was similar between the two drugs. In conclusion, our study suggests that frovatriptan has a similar efficacy of almotriptan in the short-term, while some advantages are observed during long-term treatment.

Show MeSH
Related in: MedlinePlus